EJNMMI reports最新文献

{"title":"Real world experience with [^99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry.","authors":"Pete Tually, Virginia García Quinto, Yehia Omar, Fuad Novruzov, Ryan Yudistiro, Mike Sathekge, Geoffrey Currie, Paul Galette, Neel Patel, Tracey Brown, Gabriel Bolland, Rebecca Lo Bue, David Cade","doi":"10.1186/s41824-024-00226-4","DOIUrl":"10.1186/s41824-024-00226-4","url":null,"abstract":"<p><strong>Purpose: </strong>[^99mTc]Tc-HYNIC-iPSMA is a novel technetium-99m-labelled small molecule inhibitor of the prostate-specific membrane antigen (PSMA) for detecting prostate cancer (PC). The objective of this registry was to collect and evaluate [^99mTc]Tc-HYNIC-iPSMA patient data and images to establish the safety and tolerability, and clinical utility of this agent in imaging at different stages of PC.</p><p><strong>Methods: </strong>Patients 18 to 80 years old with primary staging and metastatic PC were eligible. Patients unable to perform prescribed examinations, undergo a [^99mTc]Tc-HYNIC-iPSMA planar and SPECT or SPECT/CT (when available), or sign a patient informed consent form were excluded from the registry. All eligible patients underwent a screening and baseline visit before imaging with [^99mTc]Tc-HYNIC-iPSMA. The primary safety endpoint was assessed by collecting and grading all treatment-related adverse events using the Common Terminology Criteria for Adverse Events. Patients were followed until disease progression, death, serious or intolerable adverse events, registry termination by the sponsor, patient withdrawal, or lost to follow-up. Analysis was planned for when data was available from 40 enrolled patients.</p><p><strong>Results: </strong>40 patients enrolled in 6 countries and received [^99mTc]Tc-HYNIC-iPSMA tracer administration followed by planar and SPECT imaging. Of the 40 patients included, investigators reported a change in management due to the [^99mTc]Tc-HYNIC-iPSMA imaging in 17/40 of patients (42.5%). No adverse events were reported.</p><p><strong>Conclusions: </strong>[^99mTc]Tc-HYNIC-iPSMA is a promising option to identify PSMA-positive prostate cancer on SPECT and could improve patient access to PSMA imaging worldwide.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"43"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive role of [¹⁸F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients.","authors":"Magdi A Ali, Omar Shebl Zahra, Mohmed I Morsi, Mohamed M El Safwany, Shaymaa Essam El Feky","doi":"10.1186/s41824-024-00233-5","DOIUrl":"10.1186/s41824-024-00233-5","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this study was to evaluate the predictive value of ¹⁸F-fluorodeoxyglucose [¹⁸F]FDG positron emission tomography (PET-CT) radiomic parameters in relation to KRAS/BRAF/EGFR mutations in patients with metastatic colorectal cancer (mCRC).</p><p><strong>Methods: </strong>Blood samples were collected from 90 mCRC patients to assess KRAS G13V, BRAF V600E, and EGFR exon 20 mutations. [¹⁸F]FDG PET-CT scans were performed, and radiomic parameters, including the SUV max, max TBR, total MTV, and total TLG, were calculated and correlated with different genotypes and haplotypes of the aforementioned mutations.</p><p><strong>Results: </strong>The SUV max, TLG, and TBR were significantly greater in patients with the KRAS G13V and BRAF V600E mutations than in patients with the wild-type genotype. The SUVmax was also significantly greater in patients with EGFR exon 20 mutations. Haplotype analysis revealed that the SUVmax was significantly greater in patients with KRAS/BRAF/EGFR mutations than in other patients, with a specificity of 68.18% and sensitivity of 65.28%.</p><p><strong>Conclusion: </strong>The results suggest that [¹⁸F] FDG PET-CT radiomic parameters, particularly the SUV max, have the potential to serve as noninvasive tools for predicting the KRAS/BRAF/EGFR mutation status in mCRC patients.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"42"},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Christie score for post-treatment response assessment PET/CT in patients with head and neck squamous cell carcinoma: a safe and simple scoring system.","authors":"N Baguley, C Barker, S Bonington, S Mak, A Chander, J Price, A Datta, R Nadir, G Betts","doi":"10.1186/s41824-024-00230-8","DOIUrl":"10.1186/s41824-024-00230-8","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy with or without concurrent chemotherapy is a standard of care treatment for patients with head and neck squamous cell carcinoma (HNSCC). Upon completion, patients are referred for a post-treatment ¹⁸F-FDG PET/CT (Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) scan to help guide ongoing management by assessing for the presence or absence of residual or recurrent disease and differentiating this from post-treatment inflammation. To improve objective reporting of response, we developed the Christie score. The study aims to assess the validity of the Christie score as a response assessment tool in patients with HNSCC and to compare its performance against the widely used Hopkins score.</p><p><strong>Methods and materials: </strong>All newly diagnosed head and neck cancers between July 2018 and July 2020 were retrospectively reviewed. In total, 291 patients (224 men and 67 women) were included in the study. Patients with squamous cell carcinoma of the nasopharynx, oropharynx or oral cavity, hypopharynx or larynx were included. All other cell lineages or anatomical locations were excluded. Hopkins and Christie scores were applied to post-treatment PET/CT, and sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio assessed for each score. Fisher's exact tests and receiver-operating characteristic (ROC) curves were used to determine the ability of the Hopkins and Christie scores to differentiate residual or recurrent disease from treatment response. p values < 0.05 were considered to indicate statistical significance.</p><p><strong>Results: </strong>39 patients (13%) were confirmed to have residual or recurrent disease. This was significantly more likely in patients with positive Hopkins (p < 0.0001) and Christie (p < 0.0001) scores. The Christie score has a higher sensitivity (92% vs. 85%) and negative predictive value (99% vs. 97%) compared to Hopkins, though the differences were not statistically significant. Comparison of the ROC curves for the Hopkins and Christie score revealed no significant difference between the two scores' ability to discriminate patients with residual or recurrent disease from cases where disease is absent (p = 0.382). 'Subjectivity rates' of the 291 patients are as follows. Six patients (2.1%; 95% CI 0.76-4.5%) were assigned borderline scores on the Hopkins criteria, compared to only a single patient (0.3%; 95% CI 0-1.9%) on the Christie criteria. The 'subjectivity rate' difference is 0.017 (95% CI - 0.06 to 3.5%; p = 0.06) and the ratio is 6.0 (95% CI 0.73-276; p = 0.07).</p><p><strong>Conclusion: </strong>Our study identifies three clear results: (a) the Christie score is an excellent treatment follow-up assessment tool; (b) it is comparable with current gold standard methodology showing no statistically significant differences in performance when compared with the Hopkins score; and (c) th","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"41"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brown tumors in primary hyperparathyroidism initially interpreted as bone metastases and multiple gigantocelular tumors: case report.","authors":"Vedrana Gladić Nenadić, Marija Punda, Anita Tabain, Tomislav Jukić","doi":"10.1186/s41824-024-00229-1","DOIUrl":"10.1186/s41824-024-00229-1","url":null,"abstract":"<p><p>Brown tumors or osteitis fibrosa cystica are a rare bone metabolism disorder that may mimic cancer metastasis. It represents a late manifestation of prolonged and mostly unrecognized hyperparathyroidism. In this case report we present a 44-year-old female patient with multiple lesions detected on bone scintigraphy and ¹⁸F- FDG-PET/CT, initially interpreted as a bone metastatic disease, rather than multiple gigantocellular bone tumors. Additionally, the presented case emphasizes the importance of a multidisciplinary approach in diagnosing brown tumors as part of hyperparathyroidism, and the treatment decision.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"40"},"PeriodicalIF":0.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter- and intra-tumoral heterogeneity on [⁶⁸Ga]Ga-DOTA-TATE/[⁶⁸Ga]Ga-DOTA-TOC PET/CT predicts response to [¹⁷⁷Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients.","authors":"Camila Gadens Zamboni, Ayca Dundar, Sanchay Jain, Marc Kruzer, Bradley T Loeffler, Stephen A Graves, Janet H Pollard, Sarah L Mott, Joseph S Dillon, Michael M Graham, Yusuf Menda, Ahmad Shariftabrizi","doi":"10.1186/s41824-024-00227-3","DOIUrl":"10.1186/s41824-024-00227-3","url":null,"abstract":"<p><strong>Background: </strong>Indices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [¹⁷⁷Lu]Lu-DOTA-TATE PRRT.</p><p><strong>Methods: </strong>NET patients who underwent [¹⁷⁷Lu]Lu-DOTA-TATE therapy at the University of Iowa from August 2018 to February 2021 were retrospectively evaluated. Radiomic features on the pre-PRRT somatostatin receptor PET/CT were evaluated using a custom MIM Software® LesionID workflow. Conventional PET/CT metrics of tumor burden, such as somatostatin receptor expression and tumor volume, were calculated in addition to the indices of tumor heterogeneity for each lesion (intra-lesional) and then summarized across all lesions throughout the body (inter-lesional). Endpoints included post-PRRT 24-month time to progression (TTP) and overall survival (OS). Cox regression models were used to assess the predictive ability of the imaging factors on post-PRRT 24-month TTP and OS. LASSO-penalized Cox regression was used to build a multivariable model for each outcome.</p><p><strong>Results: </strong>Eighty patients with a mean age of 65.1 years were included, with most (71.3%) completing 4 cycles of PRRT. Median TTP was 19.1 months, and OS at 60 months was 50%. A large degree of variability between patients was evidenced for imaging features related to somatostatin receptor expression. On multivariable analysis, total receptor expression and mean liver-corrected SUVmean were selected for 24-month TTP. The model was not able to significantly predict progression (C-statistic = 0.58, 95% CI 0.50-0.62). Total receptor expression and mean skewness were selected for OS. The resulting model was able to significantly predict death (C-statistic = 0.62, 95% CI 0.53-0.67), but the predictive ability was limited, as evidenced by the low C-statistic.</p><p><strong>Conclusions: </strong>Our exploratory analysis provides preliminary results showing that imaging indices of inter- and intra-tumor heterogeneity from pretreatment PET/CT images may potentially predict treatment efficacy in NET patients undergoing [¹⁷⁷Lu]Lu-DOTA-TATE therapy. However, prospective evaluation in a larger cohort is needed to further assess whether a comprehensive characterization of tumor heterogeneity within a patient can help guide treatment decisions.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142756083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [¹⁸F]Fluciclovine.","authors":"Cato C Loeff, Willemijn van Gemert, Bastiaan M Privé, Inge M van Oort, Rick Hermsen, Diederik M Somford, James Nagarajah, Linda Heijmen, Marcel J R Janssen","doi":"10.1186/s41824-024-00228-2","DOIUrl":"10.1186/s41824-024-00228-2","url":null,"abstract":"<p><strong>Aim: </strong>The objective of this study was to compare the detection rates of [¹⁸F]PSMA-1007 and [¹⁸F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.2-5.0 µg/L).</p><p><strong>Methods: </strong>This was a prospective, single-center (Radboudumc; Nijmegen, The Netherlands), comparative phase II diagnostic imaging study (NCT04239742). The main inclusion criteria were histologically proven adenocarcinoma of the prostate, BCR after radical treatment with two consecutive (rising) PSA values (0.2-5.0 µg/L). Patients underwent both [¹⁸F]PSMA-1007 PET/CT and [¹⁸F]Fluciclovine PET/CT within two weeks. Both scans were blindly scored by three independent nuclear medicine physicians. Hereafter, a result per scan and region was generated by consensus. The primary outcome was to compare the detection rate on a patient and region level. Secondary objectives were to determine detection rate stratified for PSA value, inter-reader agreement, and SUV measurements. For lesion confirmation a composite reference score was established using follow-up data.</p><p><strong>Results: </strong>Data of fifty patients were included, median age of 71 (IQR: 67-74) years and median PSA value of 0.38 (IQR: 0.30-1.55) µg/L. Detection rates were 68% (34/50) for [¹⁸F]PSMA-1007 and 42% (21/50) for [¹⁸F]Fluciclovine on a patient level (p < 0.001). Detection rates stratified for PSA value of [¹⁸F]PSMA-1007 in comparison with [¹⁸F]Fluciclovine were for PSA 0.2-0.5 µg/L; 60.7% versus 25.0% (p = 0.002); and for PSA ≥ 0.5 µg/L; 77.3% versus 63.6% (p = 0.250). There was a trend for higher inter-reader agreement with [¹⁸F]PSMA-1007. SUV_max (p < 0.001) was significantly higher for [¹⁸F]PSMA-1007 in comparison to [¹⁸F]Fluciclovine.</p><p><strong>Conclusion: </strong>In patients with early BCR of prostate cancer after radical surgery or radiotherapy, [¹⁸F]PSMA-1007 demonstrated a significantly higher detection rate than [¹⁸F]Fluciclovine. This is particularly relevant since earlier and more accurate detection of a BCR can guide salvage therapy into a tailored strategy which may improve outcomes.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT04239742. Registered 02 January 2020, https://clinicaltrials.gov/study/NCT04239742 .</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the diagnostic capacity of [¹⁸F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.","authors":"Philip Alexander Glemser, Martin Freitag, Balint Kovacs, Nils Netzer, Antonia Dimitrakopoulou-Strauss, Uwe Haberkorn, Klaus Maier-Hein, Constantin Schwab, Stefan Duensing, Bettina Beuthien-Baumann, Heinz-Peter Schlemmer, David Bonekamp, Frederik Giesel, Christos Sachpekidis","doi":"10.1186/s41824-024-00225-5","DOIUrl":"10.1186/s41824-024-00225-5","url":null,"abstract":"<p><strong>Background: </strong>To investigate the ability of artificial intelligence (AI)-based and semi-quantitative dynamic contrast enhanced (DCE) multiparametric MRI (mpMRI), performed within [¹⁸F]-PSMA-1007 PET/MRI, in differentiating benign from malignant prostate tissues in patients with primary prostate cancer (PC).</p><p><strong>Results: </strong>A total of seven patients underwent whole-body [¹⁸F]-PSMA-1007 PET/MRI examinations including a pelvic mpMRI protocol with T2w, diffusion weighted imaging (DWI) and DCE image series. Conventional analysis included visual reading of PET/MRI images and Prostate Imaging Reporting & Data System (PI-RADS) scoring of the prostate. On the prostate level, we performed manual segmentations for time-intensity curve parameter formation and semi-quantitative analysis based on DCE segmentation data of PC-suspicious lesions. Moreover, we applied a recently introduced deep learning (DL) pipeline previously trained on 1010 independent MRI examinations with systematic biopsy-enhanced histopathological targeted biopsy lesion ground truth in order to perform AI-based lesion detection, prostate segmentation and derivation of a deep learning PI-RADS score. DICE coefficients between manual and automatic DL-acquired segmentations were compared. On patient-based analysis, PET/MRI revealed PC-suspicious lesions in the prostate gland in 6/7 patients (Gleason Score-GS ≥ 7b) that were histologically confirmed. Four of these patients also showed lymph node metastases, while two of them had bone metastases. One patient with GS 6 showed no PC-suspicious lesions. Based on DCE segmentations, a distinction between PC-suspicious and normal appearing tissue was feasible with the parameters fitted maximum contrast ratio (FMCR) and wash-in-slope. DICE coefficients (manual vs. deep learning) were comparable with literature values at a mean of 0.44. Further, the DL pipeline could identify the intraprostatic PC-suspicious lesions in all six patients with clinically significant PC.</p><p><strong>Conclusion: </strong>Firstly, semi-quantitative DCE analysis based on manual segmentations of time-intensity curves was able to distinguish benign from malignant tissues. Moreover, DL analysis of the MRI data could detect clinically significant PC in all cases, demonstrating the feasibility of AI-supported approaches in increasing diagnostic certainty of PSMA-radioligand PET/MRI.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"37"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the evolution of PET/MR research: a bibliometric analysis of publication trends, leading contributors, and conceptual frameworks (2011-2023).","authors":"Jiajin Li, Chuntao Ye, Shihong Li, Guangwu Lin","doi":"10.1186/s41824-024-00224-6","DOIUrl":"10.1186/s41824-024-00224-6","url":null,"abstract":"<p><strong>Background: </strong>Positron emission tomography-magnetic resonance imaging (PET/MR) is a cutting-edge hybrid imaging technology with the potential to revolutionize medical diagnosis. This bibliometric study aims to map the research landscape of PET/MR by analyzing a curated set of Web of Science Core Collection documents from 2011 to 2023.</p><p><strong>Methods: </strong>We conducted a bibliometric analysis to map the research landscape of PET/MR, leveraging a curated dataset of 3,600 documents retrieved from the Web of Science Core Collection spanning the period from 2011 to 2023. We employed quantitative methods to assess the quantity and distribution of PET/MR studies, including patterns of change, research status, and directions. Additionally, we utilized VOSviewer software to conduct keyword co-occurrence analysis, explore collaborative networks among authors and institutions, and identify influential journals in the field.</p><p><strong>Results: </strong>Results: The analysis reveals several key insights: (1) a significant increase in the number of PET/MR publications over the past 12 years, highlighting the growing interest and activity in this field; (2) the United States and Germany as the leading countries in terms of research output and collaboration, with a growing presence of other countries such as China; (3) the Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging as the most influential journals in the field; (4) a shift in research focus from imaging techniques to clinical applications, with an increasing emphasis on prostate cancer, PSMA, and FDG imaging.</p><p><strong>Conclusions: </strong>This study provides a comprehensive overview of PET/MR research, identifying prominent trends, key researchers, and influential works. Based on these findings, we propose recommendations for future research directions in this rapidly evolving field.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous segmentation and classification of ^99mTc-DMSA renal scintigraphic images with a deep learning approach.","authors":"Jiayi Wang, Mingyan Wu, Xiemei Ruan, Jiaying Zhang, Zhengguo Chen, Yihui Zhai, Hong Xu, Ha Wu, Jeff L Zhang","doi":"10.1186/s41824-024-00223-7","DOIUrl":"10.1186/s41824-024-00223-7","url":null,"abstract":"<p><strong>Background: </strong>^99mTc-DMSA scan plays an important role in assessing functional abnormalities in kidneys. As a promising network for deep learning (DL), Mask R-CNN has the capability of simultaneously segmenting and classifying objects in images. In this study, we tested the feasibility and accuracy of Mask R-CNN in diagnosing acute pyelonephritis (APN) and segmenting kidneys in ^99mTc-DMSA scintigraphic images. Two hundred and sixty patients with suspected APN were recruited for DMSA scan, of which 358 kidneys were diagnosed as APN. Of the recruited patients, 210 were randomly selected for training and validating Mask R-CNN, and the other 50 patients' images were used for model testing. Accuracy of the results was assessed by comparing against references from human experts.</p><p><strong>Results: </strong>In the validation phase, the trained model provided segmentation masks with intersection over union (mask IoU, for segmentation accuracy) of 86.6%, and classifications with mean average precision at the bounding box IoU ≥ 50% (mAP₅₀, for classification accuracy) of 86.2%. In testing with the 50 independent patients, mask IoU of the model's segmentation was 90.3%±2.2%, and in classifying the kidneys for APN, the trained model showed accuracy of 89.0%, sensitivity of 84.8% and specificity of 97.0%. In identifying patients with any APN kidney, 3 out of 50 patients were mis-diagnosed, achieving accuracy of 94.0%.</p><p><strong>Conclusions: </strong>Mask R-CNN, designed to perform both segmentation and classification for images, showed much promise in analyzing ^99mTc-DMSA images for both accurate diagnosis of APN and kidney segmentation.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative assessment of kidney split function and mean transit time in healthy patients using dynamic ¹⁸F-FDG PET/MRI studies with denoising and deconvolution methods making use of Legendre polynomials.","authors":"Michel Destine, Alain Seret","doi":"10.1186/s41824-024-00221-9","DOIUrl":"https://doi.org/10.1186/s41824-024-00221-9","url":null,"abstract":"<p><strong>Purpose: </strong>Our objective was to assess a deconvolution and denoising technique based on Legendre polynomials compared to matrix deconvolution on dynamic ¹⁸F-FDG renography of healthy patients.</p><p><strong>Method: </strong>The study was carried out and compared to the data of 24 healthy patients from a published study who underwent examinations with ^99mTc-MAG3 planar scintigraphy and ¹⁸F-FDG PET/MRI. Due to corruption issues in some data used in the published article, post-publication measurements were provided. We have been warned that post-publication data were treated differently. The smoothing method switched from Bezier to Savitzky-Golay and the deconvolution from matrix-based (with Tikhonov Regularization) to Richardson-Lucy. A comparison of the split function and mean transit times of the published and post-publication data against our method based on Legendre polynomials was performed.</p><p><strong>Results: </strong>For split function, we only observed a good agreement between the processing methods for the ^99mTc-MAG₃ and the post-published data. No correlation was found between the split functions obtained on the ^99mTc-MAG₃ and the ¹⁸F-FDG, contrary to the published study. However, all calculated split function values for ¹⁸F-FDG and ^99mTc-MAG₃ were within the established normal range. For the mean transit time, the correlation was moderate with published data and very good with the post-publication measurements for both ^99mTc-MAG₃ and ¹⁸F-FDG. Bias of the Bland-Altman analysis of the mean transit times for ^99mTc-MAG₃ versus ¹⁸F-FDG was 1.1 min (SD 1.7 min) for the published data, - 0.11 min (SD 1.9 min) for the post-publication results and .05 min (SD 1.9 min) for our method.</p><p><strong>Conclusions: </strong>The processing methods used in the original publication and in the post-publication work were quite complex and required adaptation of the fitting parameters for each individual and each type of examination. Our method did not require any specific adjustment; the same unmodified and fully automated algorithm was successfully applied to all data.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"33"},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}